Oxford-based leading pharmatech company Exscientia deploys Artificial Intelligence to drive drug discovery. It is claimed to be a pioneer in using AI to design a novel molecule to enter the clinic. Now, this company has raised funding to identify new targets and leads for a slew of ailments such as malaria, tuberculosis, and non-hormonal contraception.
Investment from Bill & Melinda Gates Foundation
In a recent development, Exscientia announced that it has received $4.2M (nearly €3.44M) grant from Bill & Melinda Gates Foundation. With this investment, the pharmatech company will apply its AI-driven Cetaur platforms to the discovery of the new generation of therapeutic targets and leads.